Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313781 · ClinicalTrials.gov registry record · Phase 2
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT00313781 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 204 participants.
The verdict
NCT00313781, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
Interventions
- DRUG prednisone
- DRUG docetaxel
- DRUG CP-751,871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313781
The ClinicalTrials.gov registry entry for NCT00313781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which prednisone is the first listed.
NCT00313781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313781 about?
NCT00313781 is a clinical study titled "Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)". To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
What is the current status of trial NCT00313781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2006-05. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00313781?
The interventions under investigation include: prednisone (DRUG), docetaxel (DRUG), CP-751,871 (DRUG).
Who is sponsoring clinical trial NCT00313781?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.